Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 9, 2014, Pages

  van Herwaarden, Noortje ^a   den Broeder, Alfons A ^a   Jacobs, Wilco ^b   van der Maas, Aatke ^a   Bijlsma, Johannes Wj ^c   van Vollenhoven, Ronald F ^d   van den Bemt, Bart J F ^a,e  

^a SINT MAARTENSKLINIEK   (Netherlands)

^b The Health Scientist   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d KAROLINSKA INSTITUTE   (Sweden)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

CLINICAL OUTCOME; COST EFFECTIVENESS ANALYSIS; DAS28; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; INFECTION; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; META ANALYSIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOGLOBULIN G; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84928020670     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010455.pub2     Document Type: Review

References (71)

1. Botsios C, Furlan A, Ostuni P, Sfriso P, Todesco S, Punzi L. Effects of low-dose etanercept in maintaining DAS-remission previously achieved with standard-dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2007;66(Suppl II):54.
2. Chatzidionysiou K, Turesson C, Teleman A, Knight A, Lindqvist E, Larsson P, et al. Multicenter, randomised, controlled, open-label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism 2012;64(Suppl 10):776.
3. Emery P, Smolen JS, Kavanaugh A, van Vollenhoven R, Pavelka K, Durez P, et al. Maintenance of biologic-free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases 2011;70 (Suppl 3):262.
4. Fautrel B, Pham T, Tubach F, Alfaiate T, Morel J, Dernis E, et al. Tapering TNF-blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28-driven step-down strategy randomized controlled trial. Arthritis and Rheumatism 2012;64(12):4169-70.
5. Harigai M, Takeuchi T, Tanaka, Y, Matsubara T, Yamanaka H, Miyasaka N. Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Modern Rheumatology 2012;22:814-22.
6. Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381:918-29.
7. van Vollenhoven R, Østergaard M, Leirisalo-Repo M, Uhlig T, Jansson M, Klackenberg A, et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3-armed, double-blind clinical trial. Arthritis and Rheumatism 2012;64(12):4171.
8. Aletaha D. Challenging the course of RA: time for drug-free remission?. Nature Reviews Rheumatology 2010;6:442-3.
9. Awan S, Bannon C, O'Sullivan, Duffy M, Murphy E, Barry M. Sustained remission at 6 months, despite reduction in anti-TNF dosing frequency in inflammatory arthritis. Irish Journal of Medical Science 2011;181(Suppl 2).
10. Bejarano V, Conoghan P, Quinn MA, Saleem B, Emery P. Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis. Rheumatology 2010;49:1971-4.
11. Detert J, Bastion H, Listing J, Weiß A, Wassenberg S, Liebhaber A, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Annals of the Rheumatic Diseases 2013;72:844-50.
12. Emery P, Hammoudeh M, FitzGerald O, Combe B, Martin Mola E, Bukowski J, et al. Assessing maintenance of remission with reduced dose etanercept plus methotrexate, methotrexate alone or placebo in patients with early rheumatoid arthritis who achieved remission with etanercept and methotrexate: the PRIZE study. Annals of the Rheumatic Diseases. 2013; Vol. 72(Suppl 3):399.
13. Ichikawa N, Yamanaka H. Maintenance therapy for rheumatoid arthritis after remission following successful treatment using biologics. Nihon Rinsho 2007;65(7):1293-8.
14. Keystone EC, Haraoui B, Bykerk VP. Role of infliximab in the treatment of early rheumatoid arthritis. Clinical and Experimental Rheumatology 2003;21(Suppl 31):S200-S202.
15. Klarenbeek NB, van der Kooij SM, Güler-Yüksel M, van Groenendael JHLM, Han KH, Kerstens PJSM, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Annals of the Rheumatic Diseases 2011;70:315-9.
16. Kobelt G, Lekander I, Lang A, Raffeiner B, Botsios C, Geborek P. Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment. International Journal of Technology Assessment in Health Care 2011;27(3):193-200.
17. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism 2005;52(1):27-35.
18. Smolen JS, Emery P, Ferraccioli G, Samborski W, Berenbaum F, Davies O, et al. Maintenance of remission in rheumatoid arthritis patients with low-moderate disease activity following withdrawal of certolizumab pegol treatment: week 52 results from the certain study. Annals of the Rheumatic Diseases 2012;71(Suppl 3):25.
19. Tada M, Koiki T, Okano T, Sugioka Y, Wakitani S, Fukushima K, et al. Comparison of joint destruction between standard- and low-dose etanercept in rheumatoid arthritis from the Prevention of Cartilage Destruction by Etanercept (PRECEPT) study. Rheumatology 2012;51:2164-9.
20. van den Broek M, Klarenbeek NB, Dirven L, van Schaardenburg D, Hulsmans HMJ, Kerstens PJSM, et al. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Annals of the Rheumatic Diseases 2011;70:1389-94.
21. van der Kooij SM, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Guler-Yuksel M, Zwinderman AH, Kerstens PJSM, et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Annals of the Rheumatic Diseases 2009;68:914-21.
22. Villeneuve E, Nam E, Hensor JL, Wakefield E, Conoghan RJ, Green PG, et al. Preliminary results of a multicentre randomised controlled trial of etanercept and methotrexate to induce remission in patients with newly diagnosed inflammatory arthritis. Arthritis and Rheumatism 2011;63(Suppl 10):2465.
23. Remission in rheumatoid arthritis-Assessing withdrawal of disease-modifying antirheumatic drugs in a non-inferiority design. Ongoing study June 2013.
24. Randomised controlled non-inferiority study of dose reduction and withdrawal strategies of adalimumab and etanercept in rheumatoid arthritis: saving costs at what expense?. Ongoing study December 2011.
25. Potential optimalisation (expediency) and effectiveness of TNF-blockers. Ongoing study October 2011.
26. Reduction of therapy in patients with RA in ongoing remission. Ongoing study Starting date of trial not provided. Contact author for more information.
27. Stopping tumor necrosis factor-alpha inhibitors in rheumatoid arthritis. Ongoing study January 2013.
28. Dose-to-target of etanercept treatment: a dose-tapering randomised controlled trial in patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. Ongoing study May 2013.
29. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clinical and Experimental Rheumatology 2005;23(Suppl. 39):S100-S108.
30. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis and Rheumatism 2010;62(9):2569-81.
31. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 1988;31(3):315-24.
32. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Annals of the Rheumatic Diseases 2007;66(7):921-6.
33. Blumenauer BBTB, Judd M, Wells GA, Burls A, Cranney A, Hochberg MC, et al. Infliximab for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD003785]
34. Blumenauer BBTB, Cranney A, Burls A, Coyle D, Hochberg MC, Tugwell P, et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD004525]
35. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomised controlled trials. JAMA 2006;295(19):2275-85.
36. Brocq O, Millasseau E, Albert C, Grisot C, Flory P, Roux CH, et al. Effect of discontinuing TNFa antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 2009;76(4):350-5.
37. den Broeder AA, Creemers MCW, van Gestel AM, van Riel PLCM. Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-α. Rheumatology 2002;41(6):638-42.
38. den Broeder AA, van der Maas A, van den Bemt BJF. Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA. Rheumatology 2010;49(10):1801-3.
39. Doherty M, Dieppe P. The placebo response in osteoarthritis and its implications for clinical practice. Osteoarthritis Cartilage 2009;17(10):1255-62.
40. Fautrel B, Gandjbakhch F, Foltz T, Pham T, Morel J, Alfaiate T, et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step-down strategy trial based on progressive spacing of TNF-blocker injections (STRASS trial). Annals of Rheumatic Disease 2013;72(Suppl 3):72.
41. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LHD, Funovits J, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials [American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials]. Arthritis and Rheumatism 2011;63(3):573-86.
42. Fransen J, van Riel PLCM. The Disease Activity Score and the EULAR response criteria. Clinical Experimental Rheumatology 2005;23(5 Suppl 39):S93-9.
43. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
44. Higgins JPT, Green S (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
45. Kavanaugh A, Emery P, van Vollenhoven R, Cifaldi M, Shaw J, Chen N, et al. Effect of adalimumab discontinuation on patient-reported outcomes and work productivity in early rheumatoid arthritis patients who achieved low disease activity following 26 weeks of treatment:data from the OPTIMA study. Annals of the Rheumatic Diseases 2012;71(Suppl 3):663.
46. Klareskog L, Gaubitz M, Rodríguez-Valverde V, Malaise M, Dougados M, Wajdula J. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clinical Experimental Rheumatology 2011;29(2):238-47.
47. Larsen A. A radiological method for grading the severity of rheumatoid arthritis. Scandinavian Journal of Rheumatology 1973;4(4):225-33.
48. Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD005113.pub2]
49. Nawata M, Saito K, Nakayamada S, Tanaka Y. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Modern Rheumatol 2008;18:460-4.
50. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis and Rheumatism 1995;38(1):44-8.
51. Ruiz Garcia V, Jobanputra P, Burls A, Cabello JB, Gálvez Muñoz JG, Saiz Cuenca ESC, et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI: 10.1002/14651858.CD007649.pub3]
52. Saleem B, Keen H, Goeb V, Parmar R, Nizam S, Hensor EMA. Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?. Annals of Rheumatic Diseases 2010;69:1636-42.
53. Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis and Rheumatism 1971;14(6):706-20.
54. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopes-Olivo MA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD007848.pub2]
55. Singh JA, Noorbaloochi S, Singh JA. Golimumab for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD008341]
56. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42(2):244-57.
57. Smolen JS, Emery P, Fleischmann R, van Vollenhoven R, Florentius S, Santra S, et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal od adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX)-data from the OPTIMA study. Annals of the Rheumatic Diseases 2012;71(Suppl 3):516.
58. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P et al. Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis and Rheumatism 2004;50(11):3432-43.
59. Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis:RRR (remission induction by Remicade in RA) study. Annals of the Rheumatic Diseases 2010;69(7):1286-91.
60. Tanaka Y, Hirata S, Fukuyo S, Nawata M, Kubo S, Yamaoka K, et al. Discontinuation of adalimumab without functional and radiographic damage progression after achieving sustained remission in patients with rheumatoid arthritis (the HONOR study): 1-year results. Arthritis and Rheumatism 2012;64(Suppl 10):771.
61. van den Bemt BJF, den Broeder AA, Snijders GF, Hekster YA, van Riel PLCM, Benraad B, et al. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. Annals of the Rheumatic Diseases 2008;67(12):1697-701.
62. van der Bijl AE, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, ten Wolde S, Han KH, van Krugten MV, et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis and Rheumatism 2007;56(7):2129-34.
63. van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Annals of the Rheumatic Diseases 1990;49(11):916-20.
64. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. Journal of Rheumatology 2000;27(1):261-3.
65. van der Maas A, Kievit W, van den Bemt BJF, van den Hoogen FHJ, van Riel PL, den Broeder AA. Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment:an observational cohort study. Annals of the Rheumatic Diseases 2012;71(11):1849-54.
66. van der Maas A, Lie E, Christensen R, Choy E, de Man Y, van Riel P, et al. Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study. Annals of the Rheumatic Diseases 2013;72:1800-5.
67. van Vollenhoven RF, Brannemark S, Klareskog L. Dose escalation of infliximab in clinical practise: improvements seen may be explained by a regression-like effect. Annals of the Rheumatic Diseases 2004;63(4):426-30.
68. van Vollenhoven RF. How to dose infliximab in rheumatoid arthritis: new data on a serious issue. Annals of the Rheumatic Diseases 2009;48(11):1237-9.
69. Welsing PMJ, Borm GF, van Riel PLCM. Minimal clinically important difference in radiological progression of joint damage. A definition based on patient perspective. Journal of Rheumatology 2006;33(3):501-7.
70. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT. Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis and Rheumatism 2006;54(3):711-5.
71. Yoshida K, Sung Y-K, Kavanaugh A, Bae S-C, Weinblatt ME, Kishimoto M, et al. Biologic discontinuation studies: a systematic review of methods. Annals of the Rheumatic Diseases 2014;73:595-9.